Curia Expands Cell Line Development Offering with CHOZN Platform

Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies

ALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany, that enables Curia and its clients to use the CHOZN® GS-/- cell line for production of therapeutic proteins and antibodies. Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.

CHOZN® platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes high-performing CHO cell lines, paired media and feeds, optimized expression vectors and robust protocols. The glutamine synthetase GS knockout (GS-/-) cell line of the CHOZN platform is specially designed to help streamline selection, identification and scale-up of high-producing clones ideal for GMP manufacturing of recombinant protein drugs.

“We continue to strengthen our biologics development offerings from discovery through clinical manufacturing,” said Christopher Conway, President R&D, Curia. “The CHOZN GS-/- cell line platform adds a widely accepted and commercially viable cell line to our capabilities. Our integrated offering accelerates therapeutic protein and antibody production and offers seamless tech transfer for optimal flexibility.”

Curia’s protein and antibody development experts offer a track record of accelerating progress, with a timeline in as little as 12 months from cell line development to phase I drug substance, depending on the manufacturability of the candidates.

The addition of the CHOZN platform strengthens Curia’s offerings as a complement to its existing proprietary CHO cell line, providing customers with a highly versatile and broadly applicable solution.

About Curia
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8859845

Curia Expande Oferta de Desenvolvimento de Linha Celular com a Plataforma CHOZN

Curia fecha contrato de licenciamento com a MilliporeSigma para apoiar a produção de proteínas e anticorpos

ALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, anunciou hoje a assinatura de um contrato de licenciamento com a MilliporeSigma, a divisão norte-americana de Ciências da Vida da Merck KGaA, Darmstadt, Alemanha, para que a Curia e seus clientes possam usar a linha de células CHOZN® GS-/- para a produção de proteínas e anticorpos terapêuticos. Com este acordo, a linha celular CHOZN GS-/- foi integrada ao fluxo de trabalho de desenvolvimento da linha celular da Curia que está imediatamente disponível para os clientes da Curia.

A plataforma CHOZN® é um sistema de expressão de células mamíferas de Ovário de Hamster Chinês (Chinese Hamster Ovary – CHO) que permite uma seleção e aumento de escala de forma mais rápida e simples de clones de alta produção para a geração de produtos biológicos e proteínas recombinantes terapêuticas. O sistema inclui linhas celulares CHO de alto desempenho, mídia e feeds emparelhados, vetores de expressão otimizados e protocolos robustos. A linha celular geneticamente modificada de glutamina sintetase GS (GS-/-) da plataforma CHOZN foi projetada especialmente para ajudar a agilizar a seleção, identificação e ampliação de clones de alta produção ideais para a fabricação de GMP de drogas de proteína recombinante.

“Continuamos a aprimorar nossas ofertas de desenvolvimento biológico desde a descoberta até a fabricação clínica”, disse Christopher Conway, presidente de P&D da Curia. “A plataforma de linhagem celular CHOZN GS-/- adiciona uma linhagem celular amplamente aceita e comercialmente viável às nossas capacidades. Nossa oferta integrada acelera a produção terapêutica de proteínas e anticorpos e oferece transferência de tecnologia perfeita para flexibilidade ideal.”

Os especialistas em desenvolvimento de proteínas e anticorpos da Curia tem um histórico de aceleração do progresso, com uma linha do tempo de apenas 12 meses, desde o desenvolvimento da linha celular até a substância medicamentosa da fase I, dependendo da capacidade de fabricação dos candidatos.

A adição da plataforma CHOZN fortalece as ofertas da Curia como um complemento à sua existente linha proprietária de células CHO, fornecendo aos clientes uma solução altamente versátil e amplamente aplicável.

Sobre a Curia
A Curia é uma organização líder em contratos de pesquisa, desenvolvimento e fabricação que fornece produtos e serviços de P&D por meio da fabricação comercial para clientes farmacêuticos e biofarmacêuticos. Os quase 4.000 funcionários da Curia em 29 locais nos EUA, Europa e Ásia ajudam seus clientes a avançar da curiosidade para a cura. Saiba mais em CuriaGlobal.com.

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8860042

Curia étend son offre de développement de lignées cellulaires avec la plateforme CHOZN

Curia signe un accord de licence avec MilliporeSigma pour soutenir la production de protéines et d’anticorps

ALBANY, État de New York, 20 juin 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, développement et fabrication en sous-traitance de premier plan, a annoncé aujourd’hui avoir signé un accord d’octroi de licence avec MilliporeSigma, l’entreprise nord-américaine de sciences de la vie de Merck KGaA, basée à Darmstadt, en Allemagne, qui permet à Curia et à ses clients d’utiliser la lignée cellulaire CHOZN® GS-/- pour la production d’anticorps et de protéines thérapeutiques. Suite à l’accord, la lignée cellulaire CHOZN GS-/- a été intégrée dans le workflow de développement de lignées cellulaires de Curia et est immédiatement disponible pour les clients de Curia.

La plateforme CHOZN® est un système d’expression de cellule mammalienne d’ovaire de hamster chinois (Chinese Hamster Ovary, CHO) qui permet une sélection et un accroissement plus rapides et plus simples de clones très prolifiques pour la production d’agents biologiques et de protéines recombinantes thérapeutiques. Cela inclut des lignées cellulaires CHO ultra-performantes, des milieux et cultures appairés, des vecteurs d’expression optimisés et des protocoles robustes. La lignée cellulaire glutamine synthéase GS knockout (GS-/-) de la plateforme CHOZN est spécifiquement conçue pour aider à rationaliser la sélection, l’identification et l’accroissement de clones prolifiques idéaux pour la fabrication de médicaments à base de protéines recombinantes respectant les BPF.

« Nous continuons de renforcer nos offres de développement de produits biologiques de la découverte à la fabrication clinique », a déclaré Christopher Conway, président de la R&D chez Curia. « La plateforme de lignées cellulaires CHOZN GS-/- ajoute une lignée cellulaire largement acceptée et commercialement viable à nos capacités. Notre offre intégrée accélère la production d’anticorps et de protéines thérapeutiques et propose un transfert technologique harmonieux pour une flexibilité optimale. »

Les experts du développement d’anticorps et de protéines de Curia ont un historique éprouvé pour ce qui est d’accélérer le progrès, avec un calendrier de seulement 12 mois entre le développement de lignées cellulaires et la substance médicamenteuse de phase I, selon la facilité de fabrication des candidats.

L’ajout de la plateforme CHOZN renforce les offres de Curia en tant que complément de sa lignée cellulaire CHO exclusive actuelle, offrant aux consommateurs une solution ultra-polyvalente et largement applicable.

À propos de Curia
Curia est une organisation de recherche, développement et fabrication en sous-traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Basés sur 29 sites à travers les États-Unis, l’Europe et l’Asie, les près de 4 000 employés de Curia aident les clients de l’entreprise à passer de la curiosité à la guérison. Pour en savoir plus, rendez-vous sur CuriaGlobal.com.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8860042

Digital concierge Perfect.Live raises 600 000 EUR in pre-seed round to personalise and simplify access to services, developing a fully operational GPT-powered app

The team behind Perfect.Live

Perfect Live’s team includes a group of professionals bringing a wealth of experience from product management and design, global marketing and client relations from the likes of GetID, Viveo Health and Fudy.

TALLINN, Estonia, June 20, 2023 (GLOBE NEWSWIRE) — Perfect.Live (trading name of Dear Innovations OÜ), an early-stage startup specialising in luxury concierge lifestyle solutions announces 600 000 EUR raised in a recent investment round. The funding is used to further develop and enhance their innovative GPT-powered concierge service, catering to individuals who seek access to exclusive services, eliminating the time-consuming manual tasks like phone calls and emails, which are often hindered by the lack of available data and time.

The Perfect.Live app utilises state-of-the-art machine learning algorithms to provide a seamless, efficient and personalised service. The app is designed to understand the users’ needs based on the prompts they feed into the app, offering an unparalleled level of convenience. The app effectively acts as a “digital concierge” which is a term usually associated with the world of luxury hotels and restaurants.

The team behind Perfect.Live is changing that narrative. “There is no Uber for organising your life yet – and our goal is to provide just that,” says Dmitri Laush, the founder & CEO of Perfect.Live.

Top requests of the app include experiences such as access to F1 Monaco Grand Prix exclusive superyacht parties and Cannes festival events, as well as accommodation at Cote d’Azur during F1 GP and Cannes. Providing private VIP transportation, such as helicopters, boats and luxury cars, and last-minute tables at top restaurants – these kinds of requests can be managed easily through the Perfect.Live app.

The recent investment round was led by a group of Baltic investors, including Eduards Zolotuhins, managing partner and CEO at 3ED Ventures, Sergei Verbitski from Server Partners, Igor Mölder from Capital Mill and Andrei Doktorov whose previous ventures include defi.watch and many others.

The funds raised in this investment round will be allocated towards expanding the company’s development team, enhancing the app’s features and functionality, and scaling its operations to meet the growing global demand.

Perfect.Live is founded by Dmitri Laush, an angel investor and advisor backing numerous businesses in WEB3, blockchain, lifestyle and luxury. He has previously founded GetID and Admiral Markets which was one of the first adopters of online trading with financial instruments.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6befa2f3-e997-40f5-a73f-09e80d304449

Grete Grant
Growth Consultant
+372 51 08 987
Grete.grant@miltton.com

GlobeNewswire Distribution ID 1000826152

The top 5 places to do business in 2023 according to the World Citizenship Report: CS Global Partners

London, June 20, 2023 (GLOBE NEWSWIRE) — Access to opportunity is one of the most desirable qualities that any jurisdiction can offer.

This year, the 2023 World Citizenship Report measured 188 countries in the world, looking at what these nations have to offer High Net-Worth Individuals (HNWIs) and the mass affluent who are continually looking past their home borders for better opportunities.

One key motivator that was measured in the report was Economic Opportunity, which measures the overall ability of a nation to extend wealth, material comfort, and other key benefits of a strong economy to all of its citizens.

Greater access to improved business environments and employment opportunities allows individuals to participate in the economy while achieving their goals of securing their financial futures and raising the standard of living for themselves and their families. But it doesn’t end there. Apart from the supplementary benefits of social mobility, a reduction in income disparity, and greater capital formation, having the freedom to pursue key financial goals leads to significant investment in an individual’s own well-being, their families, and their communities, which, more often, is accompanied by a greater sense of purpose.

Not only have global mass affluent individuals shown to be willing to travel to access more powerful economies globally, but they also desire supportive business environments which enable them to fully realise their entrepreneurial potential.

A shift in economic growth from the West to emerging markets over the past few decades has led to new business hubs worldwide. Regions such as Asia, the Middle East, and South America have seen rapid economic growth, coupled with improved infrastructure and, in some cases, lighter regulation.

Entrepreneurs the world over are capitalizing on this, often by going through the citizenship by investment (CBI) route of a country that allows access to profitable business opportunities in booming markets across the globe.

The World Citizenship Report looks at the top business hubs globally, among other motivators for individuals looking to widen their prospects. Other motivators explored by the World Citizenship Report are Safety and Security, Quality of Life, Global Mobility, and Financial Freedom. The World Citizenship Report is based on research by London-headquartered leading government advisory and marketing firm CS Global Partners.

So which countries are the world’s most sought-after business hubs in 2023? 

5. Switzerland and Japan

Switzerland and Japan both tied at fifth place, ranking at 82.3 in the Economic Opportunity pillar.

Switzerland, the 20th biggest economy in the world, is a well-known financial hub and a great place to invest thanks to its stable economy and strong business culture. The country is also known for its innovation and flourishing start-ups in the major cities.

In addition to its positive economic outlook, Japan is noted for its internal stability. The nation is considered one of the most politically stable countries in the world, as well as one of the safest to travel in for work or business. Japan’s economy has gained momentum in 2023 with surveys of business activity indicating that the economy is growing.

4. Netherlands

Taking fourth place, the Netherlands scored 82.4 and the country continues to be a good place to start a business. Considered as the gateway to Europe, the Netherlands has a stable business climate where ambitious companies can tap into innovation ecosystems to accelerate their businesses.

3. Hong Kong (SAR) China

In third place with a score of 83.1 is Hong Kong. The country has a free-enterprise, free-trade economy and the government has traditionally adopted a policy of non-intervention in the private sector, while at the same time providing the territory with a modern and sophisticated commercial infrastructure and a sound legal and administrative framework.

2. United States of America

In second place is the United States of America. As one of the most recognised economies in the world, the USA offers a lucrative open market that is a powerful growth engine for companies of all sizes. Coupled with a predictable and stable political and judicial system where intellectual property is protected, the USA is a great place for business investment of any kind.

The country scored 83.7 in this year’s World Citizenship Report.

1. Singapore
Singapore was crowned as the best place to do business this year with a score of 84.8. Singapore has a conducive environment for business given its regulatory environment, stable and efficient infrastructure to support starting a business, access to financial intermediation and services, and enforcement of contracts. The economy makes it easy for domestic and international businesses to make their mark in the global arena.

Chantal Mabanga
CS Global Partners
+44 (0) 207 318 4343
Chantal.Mabanga@csglobalpartners.com

GlobeNewswire Distribution ID 8861047

Floship Becomes Second Recipient of Investment from FedEx Innovation Lab

The investment marks a significant milestone and signals a new era in the development of the future of global circular e-commerce fulfillment services.

HONG KONG, June 19, 2023 (GLOBE NEWSWIRE) — Leading global circular supply chain solutions provider, Floship, has announced today that it has received an investment from FedEx Innovation Lab (FIL). This investment by FIL will strengthen Floship’s capabilities to extend its service offering to new markets. Floship is poised to collaborate with FedEx to build an end-to-end digitalized fulfillment and return solution that will create smart logistics for all.

This partnership will give FedEx e-commerce customers access to Floship’s global network of warehouses and powerful logistics platform’s capabilities to streamline their e-commerce fulfillment operations. At the same time, Floship’s customers will be able to leverage FedEx global networks as well as a full range of FedEx extensive transportation options to optimize their operations.

FedEx Innovation Lab makes early-stage investments in rising start-ups to bring additional value in terms of capabilities and speed to market to start-up firms through the FedEx global network, resources, and customer base.

Josh Tsui, CEO of Floship, commented on the investment, “It’s an honor for Floship to be collaborating with FedEx. This is a significant milestone in Floship’s journey to becoming the leading circular supply chain and fulfillment solution provider worldwide. It is a testament to our e-commerce clients about the future strategic direction of Floship and enhancements to our service offering,” said Tsui.

About Floship

Floship’s global circular supply chain ecosystem solutions cover all aspects of the global supply chain, ensuring minimal operation effort for e-commerce businesses, and allowing business owners to concentrate on driving growth with investment flexibility while gaining peace of mind.

Learn more at www.floship.com or follow us on LinkedIn.

For more information about Floship, please contact:

James Linacre, PR & Communications Lead

Phone: (+852) 5333 9420

Email: pr@floship.com

GlobeNewswire Distribution ID 8860144